Cover Image
市場調查報告書

HPV感染:開發平台分析

Human Papillomavirus Infections - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 192640
出版日期 內容資訊 英文 164 Pages
訂單完成後即時交付
價格
Back to Top
HPV感染:開發平台分析 Human Papillomavirus Infections - Pipeline Review, H2 2015
出版日期: 2015年09月23日 內容資訊: 英文 164 Pages
簡介

人類乳突病毒(HPV)是影響人類皮膚和粘膜(喉嚨,口,腳,手指,指甲,肛門,子宮頸部等)的乳突病毒科所屬病毒之一種。致病因素有年齡,免疫系低,皮膚受損,個人接觸等。治療方法包含抗生素和外科手術等。

本報告提供HPV感染的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

HPV感染概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:大學/研究機關別

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 未確認階段的產品

開發中的產品:各企業

調查中的產品:大學/研究機關別

開發治療藥的企業

  • 3M Drug Delivery Systems
  • Admedus Ltd
  • Agilvax, Inc.
  • Astex Pharmaceuticals, Inc.
  • Beijing Minhai Biotechnology Co., Ltd
  • Bharat Biotech International Limited
  • Biogenomics Limited
  • BioMAS Ltd.
  • Biota Pharmaceuticals, Inc.
  • Chongqing Zhifei Biological Products Co., Ltd.
  • Crucell N.V.
  • EpiPharm AG
  • FluGen, Inc.
  • Foamix Pharmaceuticals Ltd.
  • G&E Herbal Biotechnology Co., Ltd.
  • Genticel S.A.
  • Helix BioPharma Corp.
  • Immunservice GmbH
  • Indian Immunologicals Limited
  • 化學和血清療法學會(化血研)
  • LEO Pharma A/S
  • MediGene AG
  • NanoViricides, Inc.
  • Nielsen Biosciences, Inc.
  • Novan, Inc.
  • Novartis AG
  • Organic Vaccines
  • Promius Pharma, LLC
  • RXi Pharmaceuticals Corporation
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
  • Shanghai Zerun Biotechnology Co., Ltd.
  • Spider Biotech
  • Starpharma Holdings Limited
  • Tamir Biotechnology, Inc.
  • Zydus Cadila Healthcare Limited

治療藥的評估

    單獨療法的情況

    聯合治療的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • (digoxin + furosemide)
  • 854-A
  • ABI-1968
  • aminolevulinic acid hydrochloride
  • AS-101
  • Aspidasept
  • astodrimer
  • AX-03
  • BTA-074
  • Candida Albicans Antigen
  • Cell Therapy for Human Papillomavirus Infection
  • DFD-05
  • diphencyprone
  • EPI-N06
  • GTL-002
  • Herpecide
  • HPV virus like particle vaccine
  • human papilloma virus strains 6,11 (bivalent) vaccine
  • human papilloma virus types 16 and 18 vaccine
  • human papilloma virus types 16, 18 (bivalent) virus like particle vaccine
  • human papilloma virus vaccine
  • human papilloma virus vaccine
  • human papillomavirus (tetravalent) vaccine
  • human papillomavirus serotypes 16, 31 virus like particle vaccine
  • human papillomavirus vaccine
  • human papillomavirus vaccine
  • human papillomavirus vaccine
  • human papillomavirus vaccine
  • human papillomavirus vaccine
  • human papillomavirus vaccine
  • human papillomavirus vaccine
  • hydrogen peroxide
  • imiquimod
  • ingenol mebutate
  • interferon alfa-2b (recombinant)
  • interferon alpha-2b (recombinant)
  • ISANIL-01
  • LFX-453
  • NTP-01
  • NVN-1000
  • onalespib
  • PL-202
  • PP-210
  • ProCervix
  • ranpirnase
  • RKP-00156
  • SB-105A10
  • SB-206
  • sinecatechins
  • Small Molecules for HPV Infections
  • SRT-100
  • Synthetic Peptides for Viral Infections
  • Vaccine for Cervical Cancer and Genital Warts

開發中產品的最新趨勢

暫停的計劃

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7081IDB

Summary

Global Markets Direct's, 'Human Papillomavirus Infections - Pipeline Review, H2 2015', provides an overview of the Human Papillomavirus Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Human Papillomavirus Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Human Papillomavirus Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Human Papillomavirus Infections
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Human Papillomavirus Infections and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Human Papillomavirus Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Human Papillomavirus Infections pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Human Papillomavirus Infections
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Human Papillomavirus Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Human Papillomavirus Infections Overview
  • Therapeutics Development
    • Pipeline Products for Human Papillomavirus Infections - Overview
    • Pipeline Products for Human Papillomavirus Infections - Comparative Analysis
  • Human Papillomavirus Infections - Therapeutics under Development by Companies
  • Human Papillomavirus Infections - Therapeutics under Investigation by Universities/Institutes
  • Human Papillomavirus Infections - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Human Papillomavirus Infections - Products under Development by Companies
  • Human Papillomavirus Infections - Products under Investigation by Universities/Institutes
  • Human Papillomavirus Infections - Companies Involved in Therapeutics Development
    • 3M Drug Delivery Systems
    • Admedus Ltd
    • Agilvax, Inc.
    • Astex Pharmaceuticals, Inc.
    • Beijing Minhai Biotechnology Co., Ltd
    • Bharat Biotech International Limited
    • Biogenomics Limited
    • BioMAS Ltd.
    • Biota Pharmaceuticals, Inc.
    • Chongqing Zhifei Biological Products Co., Ltd.
    • Crucell N.V.
    • EpiPharm AG
    • FluGen, Inc.
    • Foamix Pharmaceuticals Ltd.
    • G&E Herbal Biotechnology Co., Ltd.
    • Genticel S.A.
    • Helix BioPharma Corp.
    • Immunservice GmbH
    • Indian Immunologicals Limited
    • Kaketsuken K.K.
    • LEO Pharma A/S
    • MediGene AG
    • NanoViricides, Inc.
    • Nielsen Biosciences, Inc.
    • Novan, Inc.
    • Novartis AG
    • Organic Vaccines
    • Promius Pharma, LLC
    • RXi Pharmaceuticals Corporation
    • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
    • Shanghai Zerun Biotechnology Co., Ltd.
    • Spider Biotech
    • Starpharma Holdings Limited
    • Tamir Biotechnology, Inc.
    • Zydus Cadila Healthcare Limited
  • Human Papillomavirus Infections - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (digoxin + furosemide) - Drug Profile
    • 854-A - Drug Profile
    • ABI-1968 - Drug Profile
    • aminolevulinic acid hydrochloride - Drug Profile
    • AS-101 - Drug Profile
    • Aspidasept - Drug Profile
    • astodrimer - Drug Profile
    • AX-03 - Drug Profile
    • BTA-074 - Drug Profile
    • Candida Albicans Antigen - Drug Profile
    • Cell Therapy for Human Papillomavirus Infection - Drug Profile
    • DFD-05 - Drug Profile
    • diphencyprone - Drug Profile
    • EPI-N06 - Drug Profile
    • GTL-002 - Drug Profile
    • Herpecide - Drug Profile
    • HPV virus like particle vaccine - Drug Profile
    • human papilloma virus [strains 6,11] (bivalent) vaccine - Drug Profile
    • human papilloma virus [types 16 and 18] vaccine - Drug Profile
    • human papilloma virus [types 16, 18] (bivalent) virus like particle vaccine - Drug Profile
    • human papilloma virus vaccine - Drug Profile
    • human papilloma virus vaccine - Drug Profile
    • human papillomavirus (tetravalent) vaccine - Drug Profile
    • human papillomavirus [serotypes 16, 31] virus like particle vaccine - Drug Profile
    • human papillomavirus vaccine - Drug Profile
    • human papillomavirus vaccine - Drug Profile
    • human papillomavirus vaccine - Drug Profile
    • human papillomavirus vaccine - Drug Profile
    • human papillomavirus vaccine - Drug Profile
    • human papillomavirus vaccine - Drug Profile
    • human papillomavirus vaccine - Drug Profile
    • hydrogen peroxide - Drug Profile
    • imiquimod - Drug Profile
    • ingenol mebutate - Drug Profile
    • interferon alfa-2b (recombinant) - Drug Profile
    • interferon alpha-2b (recombinant) - Drug Profile
    • ISANIL-01 - Drug Profile
    • LFX-453 - Drug Profile
    • NTP-01 - Drug Profile
    • NVN-1000 - Drug Profile
    • onalespib - Drug Profile
    • PL-202 - Drug Profile
    • PP-210 - Drug Profile
    • ProCervix - Drug Profile
    • ranpirnase - Drug Profile
    • RKP-00156 - Drug Profile
    • SB-105A10 - Drug Profile
    • SB-206 - Drug Profile
    • sinecatechins - Drug Profile
    • Small Molecules for HPV Infections - Drug Profile
    • SRT-100 - Drug Profile
    • Synthetic Peptides for Viral Infections - Drug Profile
    • Vaccine for Cervical Cancer and Genital Warts - Drug Profile
  • Human Papillomavirus Infections - Recent Pipeline Updates
  • Human Papillomavirus Infections - Dormant Projects
  • Human Papillomavirus Infections - Discontinued Products
  • Human Papillomavirus Infections - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Human Papillomavirus Infections, H2 2015
  • Number of Products under Development for Human Papillomavirus Infections - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Comparative Analysis by Unknown Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Development by Companies, H2 2015 (Contd..1)
  • Products under Development by Companies, H2 2015 (Contd..2)
  • Products under Development by Companies, H2 2015 (Contd..3)
  • Products under Investigation by Universities/Institutes, H2 2015
  • Human Papillomavirus Infections - Pipeline by 3M Drug Delivery Systems, H2 2015
  • Human Papillomavirus Infections - Pipeline by Admedus Ltd, H2 2015
  • Human Papillomavirus Infections - Pipeline by Agilvax, Inc., H2 2015
  • Human Papillomavirus Infections - Pipeline by Astex Pharmaceuticals, Inc., H2 2015
  • Human Papillomavirus Infections - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2015
  • Human Papillomavirus Infections - Pipeline by Bharat Biotech International Limited, H2 2015
  • Human Papillomavirus Infections - Pipeline by Biogenomics Limited, H2 2015
  • Human Papillomavirus Infections - Pipeline by BioMAS Ltd., H2 2015
  • Human Papillomavirus Infections - Pipeline by Biota Pharmaceuticals, Inc., H2 2015
  • Human Papillomavirus Infections - Pipeline by Chongqing Zhifei Biological Products Co., Ltd., H2 2015
  • Human Papillomavirus Infections - Pipeline by Crucell N.V., H2 2015
  • Human Papillomavirus Infections - Pipeline by EpiPharm AG, H2 2015
  • Human Papillomavirus Infections - Pipeline by FluGen, Inc., H2 2015
  • Human Papillomavirus Infections - Pipeline by Foamix Pharmaceuticals Ltd., H2 2015
  • Human Papillomavirus Infections - Pipeline by G&E Herbal Biotechnology Co., Ltd., H2 2015
  • Human Papillomavirus Infections - Pipeline by Genticel S.A., H2 2015
  • Human Papillomavirus Infections - Pipeline by Helix BioPharma Corp., H2 2015
  • Human Papillomavirus Infections - Pipeline by Immunservice GmbH, H2 2015
  • Human Papillomavirus Infections - Pipeline by Indian Immunologicals Limited, H2 2015
  • Human Papillomavirus Infections - Pipeline by Kaketsuken K.K., H2 2015
  • Human Papillomavirus Infections - Pipeline by LEO Pharma A/S, H2 2015
  • Human Papillomavirus Infections - Pipeline by MediGene AG, H2 2015
  • Human Papillomavirus Infections - Pipeline by NanoViricides, Inc., H2 2015
  • Human Papillomavirus Infections - Pipeline by Nielsen Biosciences, Inc., H2 2015
  • Human Papillomavirus Infections - Pipeline by Novan, Inc., H2 2015
  • Human Papillomavirus Infections - Pipeline by Novartis AG, H2 2015
  • Human Papillomavirus Infections - Pipeline by Organic Vaccines, H2 2015
  • Human Papillomavirus Infections - Pipeline by Promius Pharma, LLC, H2 2015
  • Human Papillomavirus Infections - Pipeline by RXi Pharmaceuticals Corporation, H2 2015
  • Human Papillomavirus Infections - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H2 2015
  • Human Papillomavirus Infections - Pipeline by Shanghai Zerun Biotechnology Co., Ltd., H2 2015
  • Human Papillomavirus Infections - Pipeline by Spider Biotech, H2 2015
  • Human Papillomavirus Infections - Pipeline by Starpharma Holdings Limited, H2 2015
  • Human Papillomavirus Infections - Pipeline by Tamir Biotechnology, Inc., H2 2015
  • Human Papillomavirus Infections - Pipeline by Zydus Cadila Healthcare Limited, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Human Papillomavirus Infections Therapeutics - Recent Pipeline Updates, H2 2015
  • Human Papillomavirus Infections - Dormant Projects, H2 2015
  • Human Papillomavirus Infections - Dormant Projects (Contd..1), H2 2015
  • Human Papillomavirus Infections - Dormant Projects (Contd..2), H2 2015
  • Human Papillomavirus Infections - Dormant Projects (Contd..3), H2 2015
  • Human Papillomavirus Infections - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Human Papillomavirus Infections, H2 2015
  • Number of Products under Development for Human Papillomavirus Infections - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top